Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Awakn Life Sciences Corp. (C:AWKN)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: 301-217 Queen St West
Tel: N/A
IR: See website
Key People
George Scorsis
Independent Chairman of the Board
Anthony Tennyson
President, Chief Executive Officer, Director
Katherine Butler
Chief Financial Officer
James Collins
Chief Operating Officer
Shaun Mcnulty
Chief Scientific Officer
David Nutt
Chief Research Officer
Benjamin Sessa
Chief Medical Officer
Jonathan Held
Chief Business Officer, Secretary
Business Overview
Awakn Life Sciences Corp. is a Canada-based biotechnology company. The Company is engaged in the research, development, and commercializing of therapeutics to treat addiction with a focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe. The Company operates in the United Kingdom (UK), Ireland and Canada.
Financial Overview
For the nine months ended 31 October 2023, Awakn Life Sciences Corp revenues increased from C$0K to C$66K. Net loss before extraordinary items decreased 44% to C$2.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Foreign exchange loss (gain) increase from C$423K (expense) to C$371K (income), Sales and marketing decrease of 64% to C$310K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $6.22M as of Oct 31, 2023
Annual revenue (TTM): $0.54M as of Oct 31, 2023
EBITDA (TTM): -$5.10M as of Oct 31, 2023
Net annual income (TTM): -$5.01M as of Oct 31, 2023
Free cash flow (TTM): -$4.20M as of Oct 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,591,197 as of Oct 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization